ASND:NSD-Ascendis Pharma A/S (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 115.66

Change

0.00 (0.00)%

Market Cap

USD 6.23B

Volume

0.22M

Avg Analyst Target

USD 187.33 (+61.97%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

USD140.07B 233.80 177.21
BNTX BioNTech SE

N/A

USD68.10B 51.40 36.74
REGN Regeneron Pharmaceuticals, Inc

N/A

USD62.47B 16.69 13.10
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD51.90B 19.11 12.98
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene, Ltd

N/A

USD29.28B N/A N/A
GMAB Genmab A/S

N/A

USD29.00B 33.07 3.64
SGEN Seagen Inc

N/A

USD26.42B 40.63 36.27
RPRX Royalty Pharma plc

N/A

USD24.49B 33.25 14.58
ALNY Alnylam Pharmaceuticals, Inc

N/A

USD21.44B N/A N/A

ETFs Containing ASND

Symbol Name Weight Mer Price(Change) Market Cap
MEU:CA Mackenzie Maximum Diversi.. 0.00 % 0.56 %

N/A

USD0.02B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -30.65% 27% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.65% 27% F 11% F
Trailing 12 Months  
Capital Gain -16.20% 45% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.20% 45% F 15% F
Trailing 5 Years  
Capital Gain 795.20% 94% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 795.20% 94% A 96% A
Average Annual (5 Year Horizon)  
Capital Gain 66.51% 83% B 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.51% 83% B 89% B+
Risk Return Profile  
Volatility (Standard Deviation) 47.64% 66% D 38% F
Risk Adjusted Return 139.60% 100% A+ 98% A+
Market Capitalization 6.23B 94% A 88% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 93% A 98% A+
Price/Book Ratio 6.59 26% F 23% F
Price / Cash Flow Ratio -22.93 80% B- 81% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -61.91% 45% F 25% F
Return on Invested Capital -46.02% 51% F 17% F
Return on Assets -30.10% 36% F 10% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 12.84 5% F 3% F
Short Percent 6.16% 53% F 32% F
Beta 0.74 77% C+ 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector